QurAlis Corp
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2025 | $20 M | No. 4 | $10 to $50 million | debt, options | SEC | |
| Dec 2022 | $60 M | No. 3 | $50 to $250 million | equity | SEC | |
| Aug 2022 | $5 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| May 2020 | $33 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
QurAlis Corp chose not to state its revenue in its newest notice of a funding round (Sep 2025).
SEC Form D · Sep 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Sep 2025
That is all the official record says: QurAlis Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of QurAlis Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 27 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jason C.D. Brown | Mr. Brown is the Chief Financial Officer of the Issuer. | Sep 2025 |
| Kasper C.D. Roet | Mr. Roet is the Chief Executive Officer, President, Secretary and Treasurer of the Issuer. | Sep 2025 |
| Shafique C.D. Virani | Executive officer | Sep 2025 |
| Angela C.D. Genge | Dr. Genge is the Chief Medical Officer of the Issuer. | Mar 2023 |
| Chris C.D. Thomajan | Mr. Thomajan is the Chief Financial Officer of the Issuer. | Mar 2023 |
| Daniel C.D. Elbaum | Mr. Elbaum is the Chief Scientific Officer of the Issuer. | Mar 2023 |
| Hagen C.D. Cramer | Mr. Cramer is the Chief Production Officer of the Issuer. | Mar 2023 |
| Julio E. Vega | Mr. Vega is the Secretary of the Issuer | Mar 2023 |
| Vikas C.D. Sharma | Mr. Sharma is the Chief Business Officer of the Issuer. | Mar 2023 |
| Amy C.D. Schulman | Director | Sep 2025 |
| Anne C.D. Whitaker | Director | Sep 2025 |
| Cillian C.D. King | Director | Sep 2025 |
| Johannes C.D. Fruehauf | Director | Sep 2025 |
| Kasper C.D. Roet | Mr. Roet is the Chief Executive Officer, President, Secretary and Treasurer of the Issuer. | Sep 2025 |
| Laia C.D. Crespo-Martin | Director | Sep 2025 |
| Luc C.D. Dochez | Director | Sep 2025 |
| Michael C.D. Hutton | Director | Sep 2025 |
| Jonathan C.D. Behr | Director | Sep 2022 |
| Roel C.D. Bulthuis | Director | Sep 2022 |
| Jonathan C.D. Fleming | Director | May 2020 |
| Kasper C.D. Roet | Mr. Roet is the Chief Executive Officer, President, Secretary and Treasurer of the Issuer. | Sep 2025 |